Diagnostic-Testing Stocks Slide After Proposed Cuts to Medicare Payments for Lab Services
Shares of Labcorp (LH) and Quest Diagnostics (DGX) fell 5.9% and 6.9% respectively in premarket trading after CMS proposed cuts to Medicare payment rates for lab services, aiming to save $1B annually and align with private-sector rates. Final 2027 rates will be set in November and take effect January 1, 2027.
How this was made
The 30-second read
Why it matters
The proposal directly reduces expected Medicare revenue for major lab providers, prompting immediate stock declines.
Market read
Regulatory change creates short‑term downside risk for U.S. diagnostic‑testing companies.
What to watch
Potential offset from private‑payer growth and cost‑reduction initiatives.
Background
CMS announced a proposal to align Medicare lab payment rates with private insurers, targeting a $1 billion annual saving.
Ticker impact
CMS proposed Medicare payment cuts caused Labcorp stock to slide 5.9% in pre‑market trading.
Further downside if cuts are finalized; potential rebound if CMS revises proposal.
Regulatory change directly reduces revenue expectations for Labcorp's Medicare business.
CMS proposed Medicare payment cuts caused Quest Diagnostics stock to fall 6.9% in pre‑market trading.
Likely continued weakness pending final rule; upside if adjustments are softened.
Same regulatory action impacts Quest's Medicare revenue stream.
Market effects
Diagnostic‑testing sector faces revenue pressure from Medicare rate cuts.
U.S. healthcare stocks may see broader sell‑off.
Limited; primarily U.S. market focus.
Counterpoint
If CMS softens the cuts, current price declines may be overdone.
Key entities
- Regulatory AgencyCMS
Centers for Medicare & Medicaid Services, proposing payment cuts.
- AdministratorMehmet Oz
CMS Administrator quoted on the proposal.
